PHILADELPHIA, Dec. 18, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that GlaxoSmithKline ("GSK") has filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) for an orally disintegrating tablet formulation of a product co-developed with Eurand using the Company's Microcaps(r) taste-masking and AdvaTab(r) technologies.
GSK successfully completed a bioequivalence study of the formulation in August 2007 and if approved, expects to launch the product in late 2008 in the US. Eurand is entitled to a milestone payment from GSK upon FDA acceptance for review of the NDA.
Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are pleased that GSK continues to steadily progress this product towards commercialization and look forward to the anticipated launch in 2008."
About...